Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity

Biomedicine and Pharmacotherapy

Volumn 68, Issue 1, 2014, Pages 101-110

  El Moselhy, Mohamed A ^a   El Sheikh, Azza A K ^b  

^a Minia University   (Egypt)

^b Minia University   (Egypt)

Author keywords

Atorvastatin; Doxorubicin; Oxidative stress

Indexed keywords

ATORVASTATIN; DOXORUBICIN; OXIDATIVE STRESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; APOPTOSIS; DOWN-REGULATION; DOXORUBICIN; DRUG-INDUCED LIVER INJURY; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MALE; NITRIC OXIDE; OXIDATIVE STRESS; PYRROLES; RATS; RATS, WISTAR; UP-REGULATION;

EID: 84895070765     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.09.001     Document Type: Article

References (63)

1. Simůnek T., Stérba M., Popelová O., Adamcová M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009, 61:154-171. [PMID: 19307704].
2. Patil R.R., Guhagarkar S.A., Devarajan P.V. Engineered nanocarriers of doxorubicin: a current update. Crit Rev Ther Drug Carrier Syst 2008, 25:1-61. [PMID: 18540835].
3. Attia S.M., Bakheet S.A. Effect of dihydrokainate on the capacity of repair of DNA damage and apoptosis induced by doxorubicin. Mutagenesis 2013, 28:257-261. [PMID: 23360835].
4. Tulubas F., Gurel A., Oran M., Topcu B., Caglar V., Uygur E. The protective effects of omega-3 fatty acids on doxorubicin-induced hepatotoxicity and nephrotoxicity in rats. Toxicol Ind Health 2013, [In press (PMID: 23512535)]. http://www.ncbi.nlm.nih.gov/pubmed/23512535.
5. El-Sheikh A.A., Morsy M.A., Mahmoud M.M., Rifaai R.A., Abdelrahman A.M. Effect of coenzyme-q10 on Doxorubicin-induced nephrotoxicity in rats. Adv Pharmacol Sci 2012, 2012:981461. [PMID: 23346106].
6. Korga A., Dudka J., Burdan F., Sliwinska J., Mandziuk S., Dawidek-Pietryka K. The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin. Oxid Med Cell Longev 2012, 2012:681367. [PMID: 22530076].
7. Park J., Kanayama A., Yamamoto K., Miyamoto Y. ARD1 binding to RIP1 mediates doxorubicin-induced NF-kappaB activation. Biochem Biophys Res Commun 2012, 422:291-297. [PMID: 22580278].
8. Zhang Y.W., Shi J., Li Y.J., Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009, 57:435-445. [PMID: 19866340].
9. Andreadou I., Sigala F., Iliodromitis E.K., Papaefthimiou M., Sigalas C., Aligiannis N., et al. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol 2007, 42:549-558. [PMID: 17223128].
10. Injac R., Perse M., Obermajer N., Djordjevic-Milic V., Prijatelj M., Djordjevic A., et al. Potential hepato-protective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas. Biomaterials 2008, 29:3451-3460. [PMID: 18501960].
11. Ayla S., Seckin I., Tanriverdi G., Cengiz M., Eser M., Soner B.C., et al. Doxorubicin induced nephrotoxicity: protective effect of nicotinamide. Int J Cell Biol 2011, 2011:390238. [PMID: 21789041].
12. Athyros V.G., Tziomalos K., Karagiannis A., Mikhailidis D.P. Atorvastatin: safety and tolerability. Expert Opin Drug Saf 2010, 9:667-674. [PMID: 20553090].
13. Yoshida M., Shiojima I., Ikeda H., Komuro I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 2009, 47:698-705. [PMID: 19660469].
14. Kim Y.H., Park S.M., Kim M., Kim S.H., Lim S.Y., Ahn J.C., et al. Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats. Toxicol Mech Methods 2012, 22:488-498. [PMID: 22455613].
15. Seicean S., Seicean A., Plana J.C., Budd G.T., Marwick T.H. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012, 60:2384-2390. [PMID: 23141499].
16. Tolman K.G. The liver and lovastatin. Am J Cardiol 2002, 89:1374-1380. [PMID: 12062731].
17. Henninger C., Huelsenbeck J., Huelsenbeck S., Grösch S., Schad A., Lackner K.J., et al. The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. Toxicol Appl Pharmacol 2012, 261:66-73. [PMID: 22712078].
18. Tang S.C., Leung J.C., Chan L.Y., Eddy A.A., Lai K.N. Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy. Kidney Int 2008, 73:288-299. [PMID: 18033243].
19. Zhang W., Li Q., Wang L., Yang X. Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats. Pediatr Nephrol 2008, 23:2185-2194. [PMID: 18791746].
20. Ozbek E., Cekmen M., Ilbey Y.O., Simsek A., Polat E.C., Somay A. Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways. Ren Fail 2009, 31:382-392. [PMID: 19839839].
21. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol 1978, 52:302-310. [PMID: 672633].
22. Sastry K.V., Moudgal R.P., Mohan J., Tyagi J.S., Rao G.S. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem 2002, 306:79-82. [PMID: 12069417].
23. Bancroft J.D., Gamble M. Theory and practice of histological techniques 2008, Churchill Livingstone. 5th ed.
24. Adams S.P., Tsang M., Wright J.M. Lipid lowering efficacy of atorvastatin. Cochrane Database Syst Rev 2012, 12:CD008226. [PMID: 23235655].
25. Svvs R., Trivedi P.P., Kushwaha S., Vikram A., Jena G.B. Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice. J Physiol Biochem 2013, 69:513-525. [PMID: 23385671].
26. Acar Z., Kale A., Turgut M., Demircan S., Durna K., Demir S., et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2011, 58:988-989. [PMID: 21851890].
27. Sieczkowski E., Lehner C., Ambros P.F., Hohenegger M. Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer 2010, 126:2025-2035. [PMID: 19739078].
28. Ajith T.A., Anu V., Riji T. Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice. J Exp Ther Oncol 2008, 7:291-298. [PMID: 19227009].
29. Li W., Fu X., Wang Y., Li X., Yang Z., Wang X., et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology 2012, 122:195-202. [PMID: 22854323].
30. Kato J.D., Wang C.T. Cardiac rehabilitation participant with sickle cell trait and statin-related hepatotoxicity: a case report. J Cardiopulm Rehabil Prev 2012, 32:182-186. [PMID: 22595892].
31. Liang W., Yang H., Wu C.F., Yu Q., Zhang D.D., Lu G.P. Effects of different statin regimens on lipid profile and serum metalloproteinases in patients with coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi 2009, 37:417-421. [PMID: 19781217].
32. Amin K.A., Abd El-Twab T.M. Oxidative markers, nitric oxide and homocysteine alteration in hypercholesterolimic rats: role of atorvastatine and cinnamon. Int J Clin Exp Med 2009, 2:254-265. [PMID: 19918318].
33. Heeba G.H., Abd-Elghany M.I. Effect of combined administration of ginger (Zingiber officinale Roscoe) and atorvastatin on the liver of rats. Phytomedicine 2010, 17:1076-1081. [PMID: 20576411].
34. Llacuna L., Fernández A., Montfort C.V., Matías N., Martínez L., Caballero F., et al. Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury. J Hepatol 2011, 54:1002-1010. [PMID: 21145825].
35. Ravi D., Das K.C. Redox-cycling of anthracyclines by thioredoxin system: increased superoxide generation and DNA damage. Cancer Chemother Pharmacol 2004, 54:449-458. [PMID: 15290096].
36. Koka S., Das A., Zhu S.G., Durrant D., Xi L., Kukreja R.C. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 2010, 334:1023-1030. [PMID: 20543097].
37. Cecen E., Dost T., Culhaci N., Karul A., Ergur B., Birincioglu M. Protective effects of silymarin against doxorubicin-induced toxicity. Asian Pac J Cancer Prev 2011, 12:2697-2704. [PMID: 22320977].
38. Abo-Salem O.M. The protective effect of aminoguanidine on doxorubicin-induced nephropathy in rats. J Biochem Mol Toxicol 2012, 26:1-9. [PMID: 22287321].
39. Abd El-Aziz T.A., Mohamed R.H., Pasha H.F., Abdel-Aziz H.R. Catechin protects against oxidative stress and inflammatory-mediated cardiotoxicity in adriamycin-treated rats. Clin Exp Med 2012, 12:233-240. [PMID: 22080234].
40. Inagaki R., Taniguchi T., Sakai T., Hayashi N., Ishii Y., Muramatsu I. Anticancer drugs inhibit induction of NO synthase in rat in vivo. Gen Pharmacol 1999, 32:185-188. [PMID: 10188617].
41. Vásquez-Vivar J., Martasek P., Hogg N., Masters B.S., Pritchard K.A., Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 1997, 36:11293-11297. [PMID: 9333325].
42. Xi L., Zhu S.G., Das A., Chen Q., Durrant D., Hobbs D.C., et al. Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. Nitric Oxide 2012, 26:274-284. [PMID: 22484629].
43. Riganti C., Rolando B., Kopecka J., Betta P.G., Ghigo D., Bosia A. Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. Mol Pharm 2013, 10:161-174. [PMID: 16450390].
44. Ito D., Ito O., Mori N., Muroya Y., Cao P.Y., Takashima K., et al. Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats. J Hypertens 2010, 28:2278-2288. [PMID: 20724941].
45. Fiore M.C., Jimenez P.M., Cremonezzi D., Juncos L.I., García N.H. Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake. Am J Physiol Renal Physiol 2011, 301:F263-F270. [PMID: 21543414].
46. Shen K.P., Lin H.L., Chang W.T., An L.M., Chen I.J., Wu B.N. Suppression of inflammatory response and endothelial nitric oxide synthase downregulation in hyperlipidaemic C57BL/6J mice by eugenosedin-A. J Pharm Pharmacol 2011, 63:860-868. [PMID: 21585385].
47. Ajamieh H., Farrell G., Wong H.J., Yu J., Chu E., Chen J., et al. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation. J Gastroenterol Hepatol 2012, 27:1353-1361. [PMID: 22432744].
48. Duquaine D., Hirsch G.A., Chakrabarti A., Han Z., Kehrer C., Brook R., et al. Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med 2003, 8:101-107. [PMID: 14518612].
49. Pacher P., Liaudet L., Bai P., Mabley J.G., Kaminski P.M., Virág L., et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003, 107:896-904. [PMID: 12591762].
50. Deng S., Kruger A., Schmidt A., Metzger A., Yan T., Gödtel-Armbrust U., et al. Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice. Naunyn Schmiedebergs Arch Pharmacol 2009, 380:25-34. [PMID: 19308358].
51. Vilà L., Rebollo A., Adalsteisson G.S., Alegret M., Merlos M., Roglans N., et al. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol 2011, 251:32-40. [PMID: 21122807].
52. Valerio A., Cardile A., Cozzi V., Bracale R., Tedesco L., Pisconti A., et al. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest 2006, 116:2791-2798. [PMID: 16981010].
53. Qi X.F., Zheng L., Lee K.J., Kim D.H., Kim C.S., Cai D.Q., et al. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis 2013, 4:e518. [PMID: 23449454].
54. Zolnierczyk J.D., Borowiak A., Hikisz P., Cebula-Obrzut B., Błoński J.Z., Smolewski P., et al. Promising anti-leukemic activity of atorvastatin. Oncol Rep 2013, 9:2065-2071. [PMID: 23440293].
55. Doyon M., Hale T.M., Huot-Marchand J.E., Wu R., de Champlain J., DeBlois D. Does atorvastatin induce aortic smooth muscle cell apoptosis in vivo?. Vascul Pharmacol 2011, 54:5-12. [PMID: 20951229].
56. Cai A., Zheng D., Dong Y., Qiu R., Huang Y., Song Y., et al. Efficacy of Atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction. Acta Biochim Biophys Sin (Shanghai) 2011, 43:857-866. [PMID: 21983658].
57. Yee S.B., Pritsos C.A. Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase. Arch Biochem Biophys 1997, 347:235-241. [PMID: 9367530].
58. Nithipongvanitch R., Ittarat W., Cole M.P., Tangpong J., Clair D.K., Oberley T.D. Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)?. Antioxid Redox Signal 2007, 9:1001-1008. [PMID: 17508921].
59. Dudka J., Gieroba R., Korga A., Burdan F., Matysiak W., Jodlowska-Jedrych B., et al. Different effects of resveratrol on dose-related Doxorubicin-induced heart and liver toxicity. Evid Based Complement Alternat Med 2012, 2012:606183. [PMID: 23258992].
60. Han D., Hanawa N., Saberi B., Kaplowitz N. Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol 2006, 291:G1-G7. [PMID: 16500922].
61. Buchholz T.A., Garg A.K., Chakravarti N., Aggarwal B.B., Esteva F.J., Kuerer H.M., et al. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 2005, 11:8398-8402. [PMID: 16322301].
62. Han D., Ybanez M.D., Ahmadi S., Yeh K., Kaplowitz N. Redox regulation of tumor necrosis factor signaling. Antioxid Redox Signal 2009, 11:2245-2263. [PMID: 19361274].
63. Taye A., El-Sheikh A.A. Lectin-like oxidized low-density lipoprotein receptor 1 pathways. Eur J Clin Invest 2013, 43:740-745. [PMID: 23594336].